Astellas and Potenza partner in immuno- oncology
This article was originally published in Scrip
Japan's Astellas is hoping to shore up its oncology offerings by developing and delivering second-generation immune-oncology therapies through a partnership with Cambridge, Massachusetts-based Potenza.
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.